Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In separate trials, Takeda’s Nesina and BMS/AstraZeneca’s Onglyza demonstrated neither cardiovascular benefit nor harm in type 2 diabetics at increased risk for such events. The DPP-4 inhibitors also were not associated with increased rates of pancreatitis, which has been a safety concern for the class.
You may also be interested in...
Nothing To SAVOR For Bristol/AZ From Phase IV Results
Bristol and AstraZeneca announced mixed results from a post-marketing study for their diabetes drug Onglyza that will likely have no commercial ramifications for the drug, which has been a disappointment since its launch in 2009.
FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.
Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.